To vaccinate or to screen - Is that the question?

International Journal of Health Planning and Management

Volumn 23, Issue 1, 2008, Pages 69-78

  Hann, Alison ^a   Peckham, Stephen ^b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Cervical cancer; Ethics; HPV; Policy; Public health; Vaccination

Indexed keywords

WART VIRUS VACCINE;

CANCER; ETHICS; HEALTH POLICY; HEALTH RISK; IMMUNIZATION; PUBLIC HEALTH; VACCINATION;

ANTIBODY RESPONSE; ARTICLE; CANCER SCREENING; CLINICAL TRIAL; DRUG COST; DRUG EFFICACY; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HIGH RISK POPULATION; HUMAN; MASS IMMUNIZATION; MEDICAL ETHICS; RISK ASSESSMENT; UNITED KINGDOM; UTERINE CERVIX CANCER; VACCINATION; VERRUCA VULGARIS;

ADOLESCENT; ADULT; CLINICAL TRIALS AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS;

EURASIA; EUROPE; UNITED KINGDOM; WESTERN EUROPE;

HUMAN PAPILLOMAVIRUS;

EID: 42549084245     PISSN: 07496753     EISSN: 10991751     Source Type: Journal    
DOI: 10.1002/hpm.918     Document Type: Article

References (28)

1. Allen T. 2007. 'Merk's Murky Dealings: HPV Vaccine Lobby Backfires' Spinwatch available at www.spinwatch.org/content/view/4080/9/accessed 9th August 2007.
2. Austoker J. 1994. Screening for cervical cancer. Br Med J 309: 241-247.
3. Cancer Research UK. 2007. UK Cervical Cancer statistics website http://info.cancerresearch-uk.org/cancerstats/types/cervix/?a=5441 Accessed 24th August 2007.
4. Chaves SS, Gargiullo P, Zhang JX, et al. 2007. Loss of vaccine induced immunity to varicella over time. N Engl J Med 356: 1121-1129.
5. Curtis P. 2007. Cervical cancer vaccine for all women could cut cases by half - study. The Guardian Friday 1st June 2007.
6. DoH. 2000. DoH Cervical Cancer Screening Programme, England: 1999-2002, Department of Health Statistical Bulletin 2000/30.
7. Dunne EF, Unger ER, Sternberg M, et al. 2007. Prevalence of HPV infection among females in the United States. JAMA 297(8): 813-819.
8. Fahey M, Irwing L, Macaskill P. 1995. Meta analysis of pap test accuracy. Am J Epidemiol 336: 1180.
9. Fisher B. 2006. Merk's Gaurdasil Vaccine Not Proven Safe for Little Girls. National Vaccine Information Centre Press Release June 27, available at: http://www.nvic.org/pressreleases/pr6270/pr6270gardasil.htm
10. Frame PS, Frame JS. 1998. Determinants of cancer screening frequency: the example of screening for cervical cancer. J Am Board Fam Pract 11: 87-95.
11. Harper D, Franco E, Wheeler C, et al. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. The Lancet 364(9447): 1757-1765.
12. Ho GYF, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervical human papillomavirus infection in young women. N Engl J Med 338(7): 423-428.
13. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. 2006. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol 102(1): 54-60.
14. Langham S, Gillam S, Thorogood M. 1995. The carrot, the stick and the general practitioner: how have changes in financial incentives affected health promotion activity in general practice? Br J Gen Pract 45: 665-668.
15. Laurance J. 2007. Is the new cervical cancer vaccine as good as it's claimed? The Independent 12th June.
16. Lippman A, Melnychuk R, Shimmin C, Boscoe M. 2007. Human papillomavirus, vaccines and women's health: questions and cautions. Can Med Assoc J 28th August, available online at www.cmaj.ca
17. McClean G, Sutton M, Guthrie B. 2006. Deprivation and quality of primary care services: evidence for persistence of the inverse care law from the UK Quality and Outcomes Framework. J Epidemiol Community Health 60(11): 917-922.
18. Muñoz N, Bosch FX, de Sanjosé S, et al. 2003. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 348: 518-527.
19. Peto J, Gilham C, Fletcher O, Mathews F. 2004. The cervical cancer epidemic that screening has prevented in the UK. The Lancet 364(9430): 249-256.
20. Petticrew M, Sowden A, Lister-Sharp D. 2001. False negative results in screening programmes: medical, psychological and other implications. Int J Technol Assess Health Care 17(2): 164-170.
21. Public Health Agency of Canada. 2007. What everyone should know about human papillomavirus (HPV): questions and answers, available: www.phac-aspc.gc.ca/std-mts/hpv-vph/hpv-vph-qaqr_e.html (accessed 19th July 2007).
22. Raffle A, Alden B, Quinn M, Babb PJ, Brett MT. 2003. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormaility and modelling of cases and deaths prevented. Br Med J 326: 901.
23. Villa LL, Costa RLR, Petta CA, et al. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) LI virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multi-centre phase II efficacy trial. Lancet Oncol 6(5): 271-278.
24. Wilson R. 2000. Screening for breast and cervical cancer as a common cause for litigation. Br Med J 320(7246): 1352-1353.
25. Wilson S, Lister H. 2002. How can we develop a cost effective quality cervical cancer screening programme? Br J Gen Pract 52(479): 485-490.
26. Wilson S, Woodman C. 1995. Assessing the effectiveness of cervical screening. Clin Obstet Gynecol 38(3): 577-584.
27. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. 2003. Am J Epidemiol 348: 518-527.
28. Zimmermann R. 2006. Ethical analysis of HPV vaccine policy options. Vaccine 24: 4812-4820.